In a Wall Street Journal article that was republished in Yahoo Finance, life sciences regulatory & compliance partner Joshua Oyster discussed the legal risks for compounded forms of weight-loss drugs that use the same active ingredients as FDA-approved drugs that are experiencing shortages.
Joshua notes that once all GLP-1 weight-loss drugs come off the FDA shortage list, the legal risks could be different for compounders making them on a large scale. “If entities want to comply with the FDA limitations, it’s going to limit the market share they’re going to have,” said Joshua.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.